It is interesting to note that vandetanib could downregulate the protein level of EPHB4 in CML cells, which was mediated by transcriptional repression and ubiquitin‐proteasome pathway. This evidence concerns the gene EPHB4 and chronic myelogenous leukemia, BCR-ABL1 positive.